Chronic Kidney Disease and Severe Mental Illness: Addressing Disparities in Access to Health Care and Health Outcomes

Explainable machine learning model incorporating social determinants of health to predict chronic kidney disease in type 2 diabetes patients

Background and objectives

Social determinants of health (SDOH) play a critical role in the onset and progression of chronic kidney disease (CKD). Despite the well-established role of SDOH, previous studies have not fully incorporated these factors in predicting CKD in Type 2 diabetes patients. To bridge this gap, this study aimed to develop and evaluate the machine learning (ML) models that incorporate SDOH to enhance CKD risk prediction in Type 2 diabetes patients.

Methods

Data were obtained from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), a national survey that collects comprehensive health-related data from adults across the United States. Missing data were addressed using the K-nearest neighbor imputation method, and the Synthetic Minority Oversampling Technique (SMOTE) was applied to balance class distributions. Potential predictive features were selected using correlation coefficient analysis. The dataset was partitioned into training (80%) and testing (20%) subsets, with a 3-fold cross-validation strategy applied to the training data. Seven ML models were developed for CKD risk prediction, including logistic regression (LR), decision tree (DT), K-nearest neighbor (KNN), random forest (RF), eXtreme Gradient Boosting (XGBoost), and an artificial neural network (ANN). Model performance was evaluated using multiple metrics, including the area under the receiver operating characteristic curve (AUROC), precision, recall, F1 score, accuracy, and false positive rate.

Results

The study included 19,912 Type 2 diabetes patients (weighted sample size: 818,878), among whom 2,924 (weighted 13.92%) had CKD, and 16,988 (weighted 86.08%) did not. Over half of the CKD group (50.4%) were aged 65 or older. The proportion of female patients was higher in both groups, comprising 53.8% of the CKD group and 50.5% of the non-CKD group. Among the ML models evaluated, the RF model demonstrated the highest predictive performance for CKD, with an AUROC of 0.89 (95% CI: 0.88 - 0.90), followed by the DT model (0.84, 95% CI: 0.83 - 0.85) and XGBoost (0.83, 95% CI: 0.82 - 0.84). The RF model achieved an accuracy of 0.81 (95%CI: 0.81 - 0.81), a precision of 0.79 (95%CI: 0.79 - 0.79), a recall of 0.85 (95%CI: 0.85 - 0.85), and an F1 score of 0.82 (95%CI: 0.82 - 0.82). Additionally, the RF model exhibited strong calibration, reinforcing its reliability as a predictive tool for CKD risk in individuals with Type 2 diabetes.

Conclusion

The study findings underscore the potential of ML models, particularly the RF model, in accurately predicting CKD among individuals with Type 2 diabetes. This approach not only enhances the precision of CKD prediction but also highlights the importance of addressing social and environmental disparities in disease prevention and management. Leveraging ML models with SDOH can lead to earlier interventions, more personalized treatment plans, and improved health outcomes for vulnerable populations.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40200-025-01621-9.

Albuminuria and Mental Illness Risk: Results From National Health and Nutrition Examination Survey 2005-2018 and Mendelian Randomization Analyses

BACKGROUND

Recent evidence suggests a link between albuminuria and mental illness. However, whether this association is stable, and its specific mechanisms remain unclear.

METHODS

The cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES) 2005-2018. Weighted multivariable-adjusted logistic regression, subgroup analysis, interaction tests, and restricted cubic spline (RCS) were conducted to assess the correlation between albuminuria and the risk of mental illness (depression). Subsequently, two-sample Mendelian randomization analyses were performed to investigate the relationship between albuminuria and various mental illnesses (anxiety disorder, persistent delusional disorder, schizophrenia, schizotypal personality disorder, panic disorder, post-traumatic stress disorder [PTSD], obsessive-compulsive disorder, bipolar I disorder, bipolar II disorder, depression, autism, social anxiety disorder).

RESULTS

Albuminuria was consistently found to have a significant association with the risk of depression, regardless of its classification as a continuous or outcome variable. A positive correlation was found between albuminuria and depression in different age groups, gender, race, education attainment, and those with hypertension, coronary heart disease, and diabetes. Further, there is a positive correlation between albuminuria and the occurrence of schizophrenia and persistent delusional disorder.

CONCLUSION

There is a close association between albuminuria and mental illness, with albuminuria being a risk factor for schizophrenia and persistent delusional disorder. Further research is needed to establish the specific connections.

Prevalence of Severe Mental Illness and Its Associations With Health Outcomes in Patients With CKD: A Swedish Nationwide Study

RATIONALE & OBJECTIVE

Patients with chronic kidney disease (CKD) often face mental health problems, but the burden of severe mental illness (SMI) in this population is unclear. We estimated the prevalence of SMIs among people with CKD and their associations with health outcomes.

STUDY DESIGN

Nationwide cross-sectional and cohort study.

SETTING & PARTICIPANTS

Using the Swedish Renal Registry, we identified 32,943 patients with incident CKD G3b-5 or kidney replacement therapy (KRT) between 2008 and 2020 for estimation of the prevalence of SMIs. Data about the 30,103 patients not receiving KRT were used to examine associations between SMIs and subsequent health outcomes.

EXPOSURE

Occurrence of SMIs (ie, schizophrenia, bipolar disorder, and major depressive disorder) before the date of first registration into the registry (index date), using diagnoses from inpatient or specialist outpatient care.

OUTCOME

30% decline in eGFR, initiation of KRT, and all-cause mortality.

ANALYTICAL APPROACH

Prevalence of SMIs was estimated in patients with CKD and compared with the general population using standardization with ratios adjusted for age, sex, and calendar year. Associations between SMIs and health outcomes were examined using Cox proportional hazards models.

RESULTS

The overall prevalence of SMI was 7.3% in patients with CKD, which was 56% higher than the general population. The prevalences for schizophrenia, bipolar disorder, and major depressive disorder were 0.5%, 2.1%, and 5.6%, respectively. All 3 SMIs were associated with a higher mortality rate. Schizophrenia was not associated with 30% decline in eGFR (HR, 0.92 [95% CI, 0.65-1.29]), but it was associated with a lower rate of initiating KRT (HR, 0.56 [95% CI, 0.39-0.80]). Bipolar disorder was associated with a higher rate of 30% decline in eGFR (HR, 1.47 [95% CI, 1.29-1.67]) but a lower rate of initiating KRT (HR, 0.79 [95% CI, 0.67-0.94]). Major depressive disorder was not associated with 30% decline in eGFR or initiation of KRT.

LIMITATIONS

Lack of primary care data and exclusion of individuals with CKD G1-3a.

CONCLUSIONS

Patients with CKD had a higher prevalence of SMI compared with the general population. In patients with CKD, each SMI was associated with higher mortality, and bipolar disorder was associated with a faster eGFR decline. Patients with CKD and pre-existing schizophrenia or bipolar disorder experienced a lower rate of initiating KRT.

PLAIN-LANGUAGE SUMMARY

Patients with chronic kidney disease (CKD) frequently experience mental health problems, yet the prevalence and impact of severe mental illness (SMI) in this population remain uncertain. This Swedish nationwide study revealed that the prevalence of any SMI was 7.3% among patients with CKD (0.5% for schizophrenia, 2.1% for bipolar disorder, and 5.6% for major depressive disorder), representing a 56% higher prevalence than experienced by the Swedish general population. All 3 SMIs were associated with a higher mortality rate in patients with CKD, and bipolar disorder was also associated with a faster eGFR decline. Moreover, patients with CKD and schizophrenia or bipolar disorder exhibited a lower rate of initiating kidney replacement therapy. These findings highlight the need for improved recognition and management of SMI among people with kidney disease.

Early-stage chronic kidney disease as a risk factor for suicide: a nationwide observational cohort study

BACKGROUND

Chronic kidney disease (CKD) is associated with poor psychological well-being. Whether early-stage CKD is a risk factor for suicide warrants further research.

METHODS

This nationwide, retrospective, cohort study aimed to evaluate the risk of suicide in patients with early-stage CKD and identify the associated risk factors. A total of 3.945,198 individuals aged ≥ 19 years who underwent the 2009 national health screening in South Korea were studied. Among them, 202,291 patients had early-stage CKD (estimated glomerular filtration rate (eGFR) ≥ 30 and < 60 mL/min per 1.73 m2 and/or dipstick albuminuria ≥ 1 +). The study outcome was suicide as confirmed by the nationwide death register based on death certificates.

RESULTS

The study population had a mean age of 59 ± 15 years, and 47% were male. We identified 930 suicides (incidence rate, 0.45 per 1000 person-years) in the CKD group and 11,332 suicides (incidence rate, 0.27 per 1000 person-years) in the non-CKD group. Early-stage CKD was significantly associated with an increased risk of suicide in multivariable analysis adjusted for demographic characteristics; lifestyle habits; comorbidities, including diabetes and hypertension; economic status; and depression, bipolar disorder, schizophrenia (hazard ratio, 1.18; 95% confidence interval 1.10‒1.26). Suicide incidence was higher in individuals with proteinuria but preserved kidney function (eGFR > 60 mL/min per 1.73 m2 and dipstick albuminuria > 1 +) than in those without CKD.

CONCLUSION

Healthcare providers may need to examine the mental health of patients with early-stage CKD to prevent suicide.

Improving kidney care for people with severe mental health difficulties: A thematic analysis of personal and family members' perspectives

People with severe mental health difficulties (SMHDs) often have poorer access to kidney healthcare. To better understand the barriers and facilitators to kidney healthcare for this population, we conducted interviews with nine individuals with SMHDs and four family members. Through reflexive thematic analysis, we generated three themes: (1) 'One size doesn't fit all' describes the need for individualised kidney healthcare, adapted to meet the specific needs of each person with a SMHD. (2) 'You just can't say, "I'm only dealing with your kidney here"' describes how fragmentation of physical and mental healthcare services can lead to poorer outcomes for people with SMHDs, underscoring the need for coordinated care. (3) 'Just treat me with respect' describes the impact of healthcare provider attitudes. Overall, participants praised the dedication and kindness of renal clinicians. However, some participants also described experiences of stigma and discrimination, and called for additional education for healthcare providers regarding SMHDs.

Depression Symptoms Do Not Worsen over Time in a Cohort of Patients with CKD: The Brain in Kidney Disease Study

Key Points

In a cohort of individuals with CKD and a high prevalence of depression and antidepressant use, depression symptoms did not worsen over time. This finding was consistent across all levels of eGFR impairment, including those who initiated dialysis. There were no differences in changes in depressive symptoms over time between individuals with CKD of any stage and those without CKD.

Background

The prevalence of depression is high in the CKD (20%–40%) and dialysis (30%–50%) populations. Less is known about how depressive symptoms change over time in patients with CKD.

Methods

Participants in the Brain in Kidney Disease cohort study completed a depressive symptom questionnaire (Patient Health Questionnaire-9 [PHQ-9]) and serum creatinine testing annually. We used linear mixed-effects models to examine changes in PHQ-9 scores over time and compared rates of change between participants with different ranges of eGFR impairment and those with normal eGFR.

Results

At baseline, 147 participants had normal eGFR, 424 had impaired eGFR without dialysis dependence, and 31% reported a diagnosis of depression, with a mean baseline PHQ-9 score of 4.3. Participants were followed for up to 5 years. After adjustment for factors associated with depression, mean PHQ-9 scores decreased (improved) by 0.25 points per year (95% confidence interval [CI], 0.07 to 0.42) among participants with normal eGFR (>60 ml/min per 1.73 m2) and by 0.35 points (95% CI, 0.14 to 0.56), 0.30 points (95% CI, 0.13 to 0.46), and 0.42 points (95% CI, 0.06 to 0.77) among participants with eGFR 45–59 ml/min per 1.73 m2, with eGFR 30–44 ml/min per 1.73 m2, and who developed dialysis dependence, respectively. PHQ-9 scores among participants with eGFR <30 ml/min per 1.73 m2 did not change significantly. We did not observe any statistically significant differences in mean change in PHQ-9 scores between participants with any degree of eGFR impairment and those with normal eGFR, nor between participants with dialysis dependence and those with eGFR of ≤15 ml/min per 1.73 m2. Participants with a PHQ-9 score ≥5 had 80% greater odds of immediate study attrition than participants with a PHQ-9 score of 0–4.

Conclusions

The mean PHQ-9 scores of participants were largely stable over time, and we observed no differences in change in PHQ-9 scores between those with impaired eGFR and those with normal eGFR.

Joint association of sleep onset time and sleep duration with depression in patients with chronic kidney disease: Insights from the NHANES 2015-2020

Background

The prevalence of depression among patients with chronic kidney disease (CKD) is high and closely related to poor prognosis. However, the association between sleep onset time, sleep duration, and depression in CKD patients has not been thoroughly studied.

Methods

This study utilized cross-sectional data from CKD patients who participated in the National Health and Nutrition Examination Survey from 2015 to 2020, analyzing their sleep onset time, sleep duration, and Patient Health Questionnaire-Nine. Logistic regression models and restricted cubic spline models were used to explore the association between sleep onset time, sleep duration, and depression in CKD patients.

Results

A total of 2141 CKD patients aged 20 and above were included in this study, among whom 246 (11.5 %) had depression. Compared to those reporting optimal sleep onset (22:00-23:59) and sufficient sleep duration (7-8 h), CKD patients with late sleep onset (≥24:00) and either insufficient (<7 h) or excessive (≥9 h) sleep had a significantly higher risk of depression, with adjusted OR of 2.03 (95 % CI:1.29-3.19) and 2.07 (95 % CI:1.07-4.00), respectively. Additionally, the association between sleep onset time, sleep duration, and depression showed a U-shaped pattern, with the inflection point for sleep onset time at 23:00 and for sleep duration at 7.5 h.

Conclusion

Inappropriate sleep onset time and sleep duration are significantly associated with depression in CKD patients. This association may be important to consider in clinical practice for the prevention and management of depressive symptoms in CKD patients.

Examining Disparities in the Evaluation and Management of Cesarean Birth Pain Among Patients With and Without a Psychiatric Condition

Background Postoperative pain management is an important aspect of postpartum care following cesarean delivery (CD). This study aimed to determine whether differences exist in pain assessments and opioid administration after CD between patients with psychiatric illness and those without. Methodology This was a retrospective cohort study of 490 patients who underwent CD at an urban tertiary care center. Demographic and delivery data were collected by chart review. The primary outcomes were the number of pain assessments performed, average pain score, and amount of morphine milligram equivalents (MMEs) administered to patients with and without psychiatric illness. Results A total of 389 patients without a psychiatric diagnosis were compared to 101 patients with a psychiatric diagnosis. After adjusting for baseline characteristics in all models, psychiatric history had a significant effect on pain severity (β = 0.25; 95% confidence interval (CI) (0.00, 0.49); p = 0.046) and number of pain assessments (β = -2.41; 95% CI (-4.42, -0.41); p = 0.018), but not on MME administration (incidence rate ratio = 1.31; 95% CI (0.60, 2.92); p = 0.466). Patients with a psychiatric history reported more severe pain after CD and received fewer pain assessments. There was no significant difference in the amount of pain medication administered between groups. Conclusions In this study, patients with a psychiatric diagnosis received fewer pain assessments and reported more severe post-CD pain compared to those without. Despite this difference, both groups received similar amounts of pain medication, raising concern for bias and inadequate treatment of pain in patients with a psychiatric diagnosis.

Effects of exercise dose based on the ACSM recommendations on depression in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials

Objective

To explore the impact of various exercise doses on depressive symptoms among hemodialysis patients and offer valuable guidance for the selection of optimal exercise doses in clinical practice settings.

Methods

A comprehensive systematic review was conducted across four major databases, namely, PubMed, Embase, Web of Science, and Cochrane Library, covering the period from their inception until August 2024. Exercise interventions were classified based on adherence to American College of Sports Medicine (ACSM) recommendations, dividing studies into groups with high and low/uncertain ACSM adherence. A meta-analysis was performed utilising Review Manager5.4.1 to assess the effects of ACSM adherence on depression in hemodialysis patients.

Results

This meta-analysis incorporated a total of 19 randomized controlled trials, involving 1,285 patients. The mean age of the patients ranged from 33.2 to 70 years, and the average body mass index (BMI) fluctuated between 23.3 and 28.81 kg/m2. Males accounted for a relatively larger proportion of the participants. Among these trials, 14 were classified as having high ACSM adherence, while 5 were categorized as having low or uncertain adherence. Overall, exercise markedly improved depression in hemodialysis patients (SMD: -0.63, 95% CI: -0.87, -0.39; p < 0.05). The high ACSM adherence group showed greater improvement relative to the low/uncertain adherence group (SMD: -0.66 vs. -0.56). No notable disparities were noted in the effects of exercise duration or patient age on depression outcomes between the subgroups (p = 0.86, p = 0.48).

Conclusion

Exercise interventions that exhibit high adherence to the ACSM guidelines prove to be more efficacious in alleviating depression among hemodialysis patients as compared to those with low or uncertain adherence levels.

Systematic Review Registration

https://www.crd.york.ac.uk/prospero/#myprospero.

Uncoded chronic kidney disease prevalence in secondary care: a retrospective audit with population health implications

BACKGROUND

One million patients are estimated to have undiagnosed chronic kidney disease (CKD) in England. Clinical coding in CKD is associated with improved management and lower acute kidney injury (AKI), unscheduled care and mortality risk. Primary care's role in coding CKD is well documented. However, there is scant evidence on CKD coding quality in secondary care. Primary aims: to measure total and coded/uncoded CKD prevalence on admission and discharge, and conversion of uncoded to coded CKD in secondary care. Secondary aims: to map coding status to kidney health inequality themes and to measure predictors of coding, death and AKI.

METHODS

Retrospective audit in an acute medical hospital ward in England, April 2022-February 2023. Descriptive statistics include counts/percentages for categorical data, prevalence estimates and rates. Logistic regression measured significant predictors (p = < 0.05) of receiving a diagnostic CKD code on discharge, risk of death, and of AKI.

RESULTS

Uncoded CKD prevalence using discharge estimated GFR (eGFR) was 58.7% (n = 283), equating to 1.1 cases uncoded CKD per bed/month and 13.7 cases uncoded CKD per bed/year. Conversion of uncoded to coded CKD at discharge was only 6.7%. Hypertension and advanced CKD were significant predictors of coding CKD on discharge in uncoded patients. Age, sex, indices of multiple deprivation, and AKI were significant predictors of death during admission. Advanced CKD was a significant predictor of AKI during admission.

CONCLUSIONS

Uncoded CKD is highly prevalent in an acute medical hospital ward highlighting opportunity to improve coding in another part of the health system in addition primary care.

Premature mortality and disparities in kidney healthcare for people with chronic kidney disease and severe mental health difficulties

BACKGROUND

People with severe mental health difficulties, including schizophrenia, bipolar disorder and psychosis, have higher risk of chronic kidney disease (CKD). Little was known regarding clinical outcomes and utilisation of kidney care for people with CKD and severe mental health difficulties.

METHODS

We conducted a retrospective cohort analysis of individuals with CKD attending a tertiary renal unit in London, between 2006 and 2019. Individuals with severe mental health difficulty diagnoses were identified, and differences between those with and without severe mental health difficulties were analysed.

RESULTS

Of the 5105 individuals with CKD, 112 (2.2%) had a recorded severe mental health difficulty diagnosis. The mean lifespan of those with severe mental health difficulties was 13.1 years shorter than those without severe mental health difficulties, t(1269) = 5.752, p < 0.001. People with severe mental health difficulties had more advanced CKD at their first nephrology appointment. There were no statistically significant differences between groups in the rates of kidney failure, age at onset of kidney failure, or time elapsed between first appointment and death/kidney failure. The number of inpatient admissions was similar between groups, but those with severe mental health difficulties had higher rates of emergency and ICU admissions. Among individuals on renal replacement therapy (RRT), those with severe mental health difficulties were less likely to receive a kidney transplant and peritoneal dialysis. For patients receiving haemodialysis, those with severe mental health difficulties had a higher proportion of shortened sessions, greater mean weight loss during sessions, and a higher proportion of serum potassium and phosphate levels outside normal ranges.

CONCLUSIONS

Findings illustrate a number of disparities in kidney healthcare between people with and without severe mental health difficulties, underscoring the need for interventions which prevent premature mortality and improve kidney care for this population.

Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review

BACKGROUND

Pharmacologic management of mental health illnesses in patients receiving dialysis is complex and lacking data.

OBJECTIVE

Our objective was to synthesize published data for the treatment of depression, bipolar and related disorders, schizophrenia or psychotic disorders, and anxiety disorders in adults receiving hemodialysis or peritoneal dialysis.

METHODS

We undertook a scoping review, searching the following databases: Medline, Embase, CINAHL, PsycINFO, Cochrane Library, Scopus, and Web of Science. Data on patients who received only short-term dialysis, a kidney transplant, or non-pharmacologic treatments were excluded.

RESULTS

Seventy-three articles were included: 41 focused on depression, 16 on bipolar disorder, 13 on schizophrenia and psychotic disorders, 1 on anxiety disorders, and 2 addressing multiple mental health illnesses. The majority of depression studies reported on selective serotonin reuptake inhibitors (SSRIs) as a treatment. Sertraline had the most supporting data with use of doses from 25 to 200 mg daily. Among the remaining SSRIs, escitalopram, citalopram, and fluoxetine were studied in controlled trials, whereas paroxetine and fluvoxamine were described in smaller reports and observational trials. There are limited published data on other classes of antidepressants and on pharmacological management of anxiety. Data on treatment for patients with bipolar disorder or schizophrenia and related disorders are limited to case reports.

CONCLUSION

Over half of the studies included were case reports, thus limiting conclusions. More robust data are required to establish effect sizes of pharmacological treatments prior to providing specific recommendations for their use in treating mental health illnesses in patients receiving dialysis.

The identification and management of depression in UK Kidney Care: Results from the Mood Maps Study

BACKGROUND

Depression is common in people with chronic kidney disease, yet little is known about how depression is identified and managed as part of routine kidney care.

OBJECTIVES

The primary objective was to survey all UK adult kidney centres to understand how depression is identified and managed. A secondary objective was to broadly describe the variability in psychosocial care.

DESIGN

Online survey.

METHODS

The survey comprised of three sections: (1) general kidney care, (2) psychological provision and (3) social work provision.

RESULTS

48/68 (71%) of centres responded to the general survey with 20 and 13 responses from psychological and social work module respectively. Only 31.4% reported having both in centre psychological and social work practitioners. Three centres reported no access to psychosocial provision. Of the 25 centres who reported on pathways, 36.0% reported having internal pathways for the identification and management of depression. Within services with psychological provision, screening for depression varied across modality/group (e.g., 7.1% in mild/moderate chronic kidney disease vs. 62.5% in kidney donors). Cognitive Behavioural Therapy and Acceptance and Commitment Therapy were the most common interventions offered. Most psychosocial services were aware of the National Institute for Health and Care Excellence guidelines for managing depression in long-term conditions (n = 18, 94.7%) yet few fully utilised (n = 6, 33.3%). Limited workforce capacity was evident.

CONCLUSIONS

There is considerable variability in approaches taken to identify and treat depression across UK kidney services, with few services having specific pathways designed to detect and manage depression. Workforce capacity remains a significant issue.

Social Risk Profile and Cardiovascular-Kidney-Metabolic Syndrome in US Adults

BACKGROUND

Poor cardiovascular-kidney-metabolic (CKM) health is associated with premature mortality and excess morbidity in the United States. Adverse social conditions have a prominent impact on cardiometabolic diseases during the life course. We aim to examine the association between social risk profile (SRP) and CKM multimorbidity among US adults.

METHODS AND RESULTS

We used data from the National Health and Nutrition Examination Survey from 1999 to 2018. The definition of CKM syndrome is the coexistence of subclinical or clinical cardiovascular disease, chronic kidney disease, and metabolic disorders. We classified participants by 4 CKM stages according to the different clinical severity of different forms of CKM syndrome. We calculated the summed number of positive SRP measures, including employed, high-income level, food secure, high education attainment, private insurance, owning a house, and married, as SRP scores and classified them into 4 levels by quartiles: low (0-2), lower-middle (3-4), upper-middle (5-6), and high (7-8). A total of 18 373 US adults, aged 20 to 79 years, were included in our analyses. There were 2567 (9.4%) participants with low SRP score level. Most individual SRP measures and a combined SRP score were associated with CKM stages. Compared with high SRP score level, low SRP level was associated with higher odds of having CKM stage 1 (odds ratio [OR], 1.34 [95% CI, 1.06-1.70]), CKM stage 2 (OR, 2.03 [95% CI, 1.59-2.58]), CKM stage 3 (OR, 5.28 [95% CI, 3.29-8.47]), and CKM stage 4 (OR, 5.97 [95% CI, 4.20-8.49]).

CONCLUSIONS

Cumulative social disadvantage, denoted by higher SRP burden, was associated with higher odds of CKM multimorbidity, independent of demographic and lifestyle factors.

Mental health and addiction service utilization among people living with chronic kidney disease

BACKGROUND

Mental health problems, particularly anxiety and depression, are common in patients with chronic kidney disease (CKD) and negatively impact quality of life, treatment adherence and mortality. However, the degree to which mental health and addiction services are utilized by those with CKD is unknown. We examined the history of mental health and addiction service use of individuals across levels of kidney function.

METHODS

We performed a population-based cross-sectional study using linked healthcare databases from Ontario, Canada from 2009 to 2017. We abstracted the prevalence of individuals with mental health and addiction service use within the previous 3 years across levels of kidney function [estimated glomerular filtration rate (eGFR) ≥60, 45 to <60, 30 to <45, 15 to <30, <15 ml/min/1.73 m2 and maintenance dialysis]. We calculated prevalence ratios (PRs) to compare prevalence across kidney function strata, while adjusting for age, sex, year of cohort entry, urban versus rural location, area-level marginalization and Charlson comorbidity index.

RESULTS

Of 5 956 589 adults, 9% (n = 534 605) had an eGFR <60 ml/min/1.73 m2 or were receiving maintenance dialysis. Fewer individuals with an eGFR <60 ml/min/1.73 m2 had a history of any mental health and addiction service utilization (crude prevalence range 28-31%) compared with individuals with an eGFR ≥60 ml/min/1.73 m2 (35%). Compared with an eGFR ≥60 ml/min/1.73 m2, the lowest prevalence of individuals with any mental health and addiction service utilization was among those with an eGFR of 15 to <30 ml/min/1.73 m2 {adjusted PR 0.86 [95% confidence interval (CI) 0.85 to 0.88]}, an eGFR <15 ml/min/1.73 m2 [adjusted PR 0.81 (95% CI 0.76-0.86)] and those receiving maintenance dialysis [adjusted PR 0.83 (95% CI 0.81-0.84)]. Less use of outpatient services accounted for differences in service utilization.

CONCLUSIONS

Mental health and addiction service utilization is common but less so in individuals with advanced CKD in Ontario, Canada.

Bridging the Evidence and Practice Gap in Chronic Kidney Disease: A System Thinking Approach to Population Health

Chronic kidney disease (CKD) is common, costly, and life-limiting, requiring dialysis and transplantation in advanced stages. Although effective guideline-based therapy exists, the asymptomatic nature of CKD together with low health literacy, adverse social determinants of health, unmet behavioral health needs, and primary care providers' (PCP) limited understanding of CKD result in defects in screening and diagnosis. Care is fragmented between PCPs and specialty nephrologists, with limited time, expertise, and resources to address systemic gaps. In this article, the authors define how they classified defects in care and report the current numbers of patients exposed to these defects, both nationally and in their health system Accountable Care Organization. They describe use of the health system's three-pillar leadership model (believing, belonging, and building) to empower providers to transform CKD care. Believing entailed engaging individuals to believe defects in CKD care could be eliminated and were a collective responsibility. Belonging fostered the creation of learning communities that broke down silos and encouraged open communication and collaboration between PCPs and nephrologists. Building involved constructing a fractal management infrastructure with transparent reporting and shared accountability, which would enable success in innovation and transformation. The result is proactive and relational CKD care organized around the patient's needs in University Hospitals Systems of Excellence. Systems of excellence combine multiple domains of expertise to promote best practice guidelines and integrate care throughout the system. The authors further describe a preliminary pilot of the CKD System of Excellence in primary care.

Achieving consensus on psychosocial and physical rehabilitation management for people living with kidney disease

Background

People living with chronic kidney disease (CKD) need to be able to live well with their condition. The provision of psychosocial interventions (psychological, psychiatric and social care) and physical rehabilitation management is variable across England, as well as the rest of the UK. There is a need for clear recommendations for standards of psychosocial and physical rehabilitation care for people living with CKD, and guidance for the commissioning and measurement of these services. The National Health Service (NHS) England Renal Services Transformation Programme (RSTP) supported a programme of work and modified Delphi process to address the management of psychosocial and physical rehabilitation care as part of a larger body of work to formulate a comprehensive commissioning toolkit for renal care services across England. We sought to achieve expert consensus regarding the psychosocial and physical rehabilitation management of people living with CKD in England and the rest of the UK.

Methods

A Delphi consensus method was used to gather and refine expert opinions of senior members of the kidney multi-disciplinary team (MDT) and other key stakeholders in the UK. An agreement was sought on 16 statements reflecting aspects of psychosocial and physical rehabilitation management for people living with CKD.

Results

Twenty-six expert practitioners and other key stakeholders, including lived experience representatives, participated in the process. The consensus (>80% affirmative votes) amongst the respondents for all 16 statements was high. Nine recommendation statements were discussed and refined further to be included in the final iteration of the 'Systems' section of the NHS England RSTP commissioning toolkit. These priority recommendations reflect pragmatic solutions that can be implemented in renal care and include recommendations for a holistic wellbeing assessment for all people living with CKD who are approaching dialysis, or who are at listing for kidney transplantation, which includes the use of validated measurement tools to assess the need for further intervention in psychosocial and physical rehabilitation management. It is recommended that the scores from these measurement tools be included in the NHS England Renal Data Dashboard. There was also a recommendation for referral as appropriate to NHS Talking Therapies, psychology, counselling or psychotherapy, social work or liaison psychiatry for those with identified psychosocial needs. The use of digital resources was recommended to be used in addition to face-to-face care to provide physical rehabilitation, and all healthcare professionals should be educated to recognize psychosocial and physical rehabilitation needs and refer/sign-post people with CKD to appropriate services.

Conclusion

There was high consensus amongst senior members of the kidney MDT and other key stakeholders, including those with lived experience, in the UK on all aspects of the psychosocial and physical rehabilitation management of people living with CKD. The results of this process will be used by NHS England to inform the 'Systems' section of the commissioning toolkit and data dashboard and to inform the National Standards of Care for people living with CKD.

Disasters and kidney care: pitfalls and solutions

Patients with kidney disease, especially those with kidney failure, are particularly susceptible to the adverse effects of disasters because their survival depends on functional infrastructure, advanced technology, the availability of specific drugs and well-trained medical personnel. The risk of poor outcomes across the entire spectrum of patients with kidney diseases (acute kidney injury, chronic kidney disease and kidney failure on dialysis or with a functioning transplant) increases as a result of disaster-related logistical challenges. Patients who are displaced face even more complex problems owing to additional threats that arise during travel and after reaching their new location. Overall, risks may be mitigated by pre-disaster preparedness and training. Emergency kidney disaster responses depend on the type and severity of the disaster and include medical and/or surgical treatment of injuries, treatment of mental health conditions, appropriate diet and logistical interventions. After a disaster, patients should be evaluated for problems that were not detected during the event, including those that may have developed as a result of the disaster. A retrospective review of the disaster response is vital to prevent future mistakes. Important ethical concerns include fair distribution of limited resources and limiting harm. Patients with kidney disease, their care-givers, health-care providers and authorities should be trained to respond to the medical and logistical problems that occur during disasters to improve outcomes.

Immune function, gastrointestinal hormone levels, and their clinical significance in patients with gastric ulcers complicated with depression

BACKGROUND

Gastric ulcer (GU) is a common digestive tract disease, and medical records of GU combined with depression are increasingly common. Currently, the risk factors and pathogenesis of GU complicated with depression remain unclear. Low immune function and gastrointestinal hormone levels may also be significant risk factors. Therefore, this study explored the immune function and gastrointestinal hormone levels in patients with GU combined with depression.

AIM

To explore the immune function, gastrointestinal hormone level, and clinical significance of patients with GU combined with depression.

METHODS

A retrospective analysis was conducted on 300 patients with GU combined with depression admitted to Guizhou Provincial People's Hospital from January 2021 to June 2022 as the study subjects. According to the Hamilton Depression Scale (HAMD) score, patients were divided into mild-to-moderate (n = 210) and heavy (n = 90) groups. Basic data, immune function indices [immunoglobulin A (IgA), IgM, IgG, serum CD4+ and CD8+ percentage, and CD4+/CD8+ ratio], and gastrointestinal hormone indices [serum gastrin (GAS), cholecystokinin (CCK), and motilin (MTL) levels] were collected. The basic data of the two groups were compared, and the immune function and gastrointestinal hormone indices were analyzed. Multivariate logistic regression was used to analyze the factors influencing the severity of GU complicated with depression. The receiver operating characteristic (ROC) curve and area under the ROC curve (AUC) were used to analyze the value of the immune function index, gastrointestinal hormone index, and combined index in predicting the severity of GU complicated with depression.

RESULTS

There were no marked differences in sex, age, body mass index, abdominal distension, abdominal pain, belching, nausea, vomiting, or sleep disorders between the heavy and mild-to-moderate groups (P > 0.05). There was a marked difference in the family history of depression between the heavy and mild-to-moderate groups (P < 0.05). There were significant differences in serum IgA and IgM levels and serum CD4+, CD8+, and CD4+/CD8+ ratios between the heavy and mild-to-moderate groups (P < 0.05). Multivariate analysis showed that IgA, IgM, GAS, and CCK serum levels influenced the severity of GU with depression (P < 0.05). The AUC of the ROC curve for serum IgA level predicting GU with depression severity was 0.808 [95% confidence interval (CI): 0.760-0.857], the AUC of the serum IgM level was 0.757 (95%CI: 0.700-0.814), the AUC of the serum GAS level was 0.853 (95%CI: 0.810-0.897), the AUC of the serum CCK level was 0.762 (95%CI: 0.709-0.822), the AUC of immune function (IgA, IgM) and gastrointestinal hormone levels (GAS, CCK) for the prediction of GU with depression severity was 0.958 (95%CI: 0.933-0.976).

CONCLUSION

Important factors influencing GU complicated with depression are serum IgA, IgM, GAS, and CCK indicators. They can be used as indicators to predict the severity of GU complicated with depression.

Using Bayesian networks with tabu algorithm to explore factors related to chronic kidney disease with mental illness: A cross-sectional study

While Bayesian networks (BNs) offer a promising approach to discussing factors related to many diseases, little attention has been poured into chronic kidney disease with mental illness (KDMI) using BNs. This study aimed to explore the complex network relationships between KDMI and its related factors and to apply Bayesian reasoning for KDMI, providing a scientific reference for its prevention and treatment. Data was downloaded from the online open database of CHARLS 2018, a population-based longitudinal survey. Missing values were first imputed using Random Forest, followed by propensity score matching (PSM) for class balancing regarding KDMI. Elastic Net was then employed for variable selection from 18 variables. Afterwards, the remaining variables were included in BNs model construction. Structural learning of BNs was achieved using tabu algorithm and the parameter learning was conducted using maximum likelihood estimation. After PSM, 427 non-KDMI cases and 427 KDMI cases were included in this study. Elastic Net identified 11 variables significantly associated with KDMI. The BNs model comprised 12 nodes and 24 directed edges. The results suggested that diabetes, physical activity, education levels, sleep duration, social activity, self-report on health and asset were directly related factors for KDMI, whereas sex, age, residence and Internet access represented indirect factors for KDMI. BN model not only allows for the exploration of complex network relationships between related factors and KDMI, but also could enable KDMI risk prediction through Bayesian reasoning. This study suggests that BNs model holds great prospects in risk factor detection for KDMI.

Chronic kidney disease and severe mental illness: a scoping review

BACKGROUND

People who have severe mental illness experience higher rates of long-term conditions and die on average 15-20 years earlier than people who do not have severe mental illness, a phenomenon known as the mortality gap. Long-term conditions, such as diabetes, impact health outcomes for people who have severe mental illness, however there is limited recognition of the relationship between chronic kidney disease and severe mental illness. Therefore, the aim of this scoping review was to explore the available evidence on the relationship between chronic kidney disease and severe mental illness.

METHODS

Electronic databases, including MEDLINE, Embase, CINAHL, and PsycINFO were searched. The database searches were limited to articles published between January 2000-January 2022, due to significant progress that has been made in the detection, diagnosis and treatment of both SMI and CKD. Articles were eligible for inclusion if they explored the relationship between SMI and CKD (Stages 1-5) in terms of prevalence, risk factors, clinical outcomes, and access to treatment and services. Severe mental illness was defined as conditions that can present with psychosis, including schizophrenia, schizoaffective disorder, bipolar disorder, and other psychotic disorders. Thirty articles were included in the review.

RESULTS

The included studies illustrated that there is an increased risk of chronic kidney disease amongst people who have severe mental illness, compared to those who do not. However, people who have severe mental illness and chronic kidney disease are less likely to receive specialist nephrology care, are less likely to be evaluated for a transplant, and have higher rates of mortality.

CONCLUSION

In conclusion, there is a dearth of literature in this area, but the available literature suggests there are significant health inequalities in kidney care amongst people who have severe mental illness. Further research is needed to understand the factors that contribute to this relationship, and to develop strategies to improve both clinical outcomes and access to kidney care.

Improving kidney care for people with severe mental health difficulties: a thematic analysis of twenty-two healthcare providers' perspectives

Introduction

People with severe mental health difficulties (SMHDs) and concurrent kidney disease have less access to quality kidney care and worse clinical outcomes. Our research investigates the barriers and facilitators to effective kidney care for people with SMHDs, and how care might be improved for this underserved population.

Methods

We conducted semi-structured interviews with twenty-two physical (n = 14) and mental (n = 8) healthcare professionals with experience working with people with SMHDs and concurrent kidney disease. Interview data were analysed and interpreted using reflexive thematic analysis.

Results

Four themes were generated from the data: 1. "It's about understanding their limitations and challenges, without limiting their rights" describes how some people with SMHDs need additional support when accessing kidney care due to challenges with their mental state, motivation, cognitive difficulties, or mistrust of the healthcare system. 2. "There are people falling through the cracks" describes how the separation of physical and mental healthcare, combined with under-resourcing and understaffing, results in poorer outcomes for people with SMHDs. 3. "Psychiatry is a black spot in our continuing medical education" describes how many renal healthcare providers have limited confidence in their understanding of mental health and their ability to provide care for people with SMHDs. 4. "When they present to a busy emergency department with a problem, the staff tend to go '…psych patient"" describes how stigma towards people with SMHDs can negatively impact quality of care.

Conclusion

Healthcare professionals accounts' describe how people with SMHDs and kidney disease can have favourable outcomes if they have appropriate hospital, community and social supports. Findings indicate that effective management of kidney disease for people with SMHDs requires integrated physical and mental health care, which takes an individualised "whole person" approach to addressing the interaction between kidney disease and mental health.

Caffeine intake improves the cognitive performance of patients with chronic kidney disease

Objective

Cognitive impairment is a common complication of chronic kidney disease (CKD). Caffeine intake has been reported to improve cognitive performance in several studies. However, whether the benefits of caffeine intake on cognitive function apply to patients with CKD remains unknown.

Methods

We performed a retrospective cross-sectional study based on the National Health and Nutrition Examination Survey (NHANES). The data of CKD subjects and non-CKD subjects from NHANES 2011−2014 were analyzed. Propensity score matching (PSM) was performed based on age, sex, diabetes, cancer, educational level, energy intake and protein intake to select subjects. The Consortium to Establish a Registry for Alzheimer’s Disease Word Learning Test (CERAD-WL), the CERAD Word List Recall Test (CERAD-DR), the Animal Fluency Test (AF) and the Digit Symbol Substitution Test (DSST) were used, whereby the occurrence of cognitive impairment was identified. Logistic regression models were performed to evaluate the association between caffeine intake and cognitive performance in CKD and non-CKD participants. Stratified analyses according to the stage of CKD and the urinary albumin/creatinine ratio levels were performed. Plot curves were then generalized to present a non-linear relationship, and the inflection point for each non-linear model was obtained by using a recursive algorithm.

Results

Cognitive impairment was more prevalent in CKD patients than in non-CKD subjects. For CKD patients, caffeine intake was associated with higher CERAD-WL, CERAD-DR, AF and DSST scores. For non-CKD subjects, caffeine intake was associated with higher DSST scores only. Subgroup analysis revealed that caffeine only benefited the cognitive function of patients with CKD stages 2 and 3. The analysis showed non-linear relationships of caffeine intake and cognitive function for both CKD and non-CKD subjects. The inflection point of caffeine intake for CKD patients was 279 mg/day.

Conclusion

The recommended dose of caffeine intake to improve the cognitive function of CKD patients is ≤279 mg/day.